TW201713329A - 治療癌症的方法 - Google Patents

治療癌症的方法 Download PDF

Info

Publication number
TW201713329A
TW201713329A TW105113235A TW105113235A TW201713329A TW 201713329 A TW201713329 A TW 201713329A TW 105113235 A TW105113235 A TW 105113235A TW 105113235 A TW105113235 A TW 105113235A TW 201713329 A TW201713329 A TW 201713329A
Authority
TW
Taiwan
Prior art keywords
compound
cancer
formula
foregoing
pharmaceutically acceptable
Prior art date
Application number
TW105113235A
Other languages
English (en)
Chinese (zh)
Inventor
李嘉強
尤際 李
哈利 羅戈夫
高媛
靜涵 黃
Original Assignee
波士頓生醫公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 波士頓生醫公司 filed Critical 波士頓生醫公司
Publication of TW201713329A publication Critical patent/TW201713329A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105113235A 2015-04-27 2016-04-27 治療癌症的方法 TW201713329A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562153385P 2015-04-27 2015-04-27

Publications (1)

Publication Number Publication Date
TW201713329A true TW201713329A (zh) 2017-04-16

Family

ID=56081544

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105113235A TW201713329A (zh) 2015-04-27 2016-04-27 治療癌症的方法

Country Status (16)

Country Link
US (1) US20180250261A1 (enExample)
EP (1) EP3288552A1 (enExample)
JP (2) JP2018514557A (enExample)
KR (1) KR20170141716A (enExample)
CN (1) CN107683137A (enExample)
AU (1) AU2016255034A1 (enExample)
BR (1) BR112017022958A2 (enExample)
CA (1) CA2983468A1 (enExample)
EA (1) EA201792320A1 (enExample)
HK (1) HK1252172A1 (enExample)
IL (1) IL255023A0 (enExample)
MX (1) MX2017013816A (enExample)
PH (1) PH12017501882A1 (enExample)
SG (1) SG11201708506QA (enExample)
TW (1) TW201713329A (enExample)
WO (1) WO2016176190A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2018005444A2 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
WO2022178957A1 (zh) * 2021-02-25 2022-09-01 毕庶壮 Napabucasin的制药用途
CN116173004A (zh) * 2021-11-26 2023-05-30 上海交通大学附属瑞金医院 硝呋齐特在制备用于预防或治疗肾上腺皮质癌的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20160030384A1 (en) * 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer

Also Published As

Publication number Publication date
AU2016255034A1 (en) 2017-11-02
EA201792320A1 (ru) 2018-02-28
JP2018514557A (ja) 2018-06-07
JP2021121629A (ja) 2021-08-26
IL255023A0 (en) 2017-12-31
BR112017022958A2 (pt) 2018-07-17
CN107683137A (zh) 2018-02-09
SG11201708506QA (en) 2017-11-29
WO2016176190A1 (en) 2016-11-03
MX2017013816A (es) 2018-11-12
CA2983468A1 (en) 2016-11-03
EP3288552A1 (en) 2018-03-07
PH12017501882A1 (en) 2018-03-05
KR20170141716A (ko) 2017-12-26
US20180250261A1 (en) 2018-09-06
HK1252172A1 (zh) 2019-05-17

Similar Documents

Publication Publication Date Title
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US20180085341A1 (en) Methods for treating cancer
KR20170082494A (ko) 결정 형태의 글루타미나아제 억제제
JP2016516776A (ja) がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
TW201731500A (zh) 用於治療癌症的方法
JP2020169222A (ja) 癌を治療するための方法
US10646464B2 (en) Methods for treating cancer
WO2018005444A2 (en) Methods for treating cancer
KR102382771B1 (ko) 증식성 질환을 위한 조합 치료
US20180098959A1 (en) Methods for treating cancer
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안